Plus   Neg

Meridian Bioscience Cuts FY19 Outlook, Suspends Dividend - Quick Facts

While reporting financial results for the second quarter, Meridian Bioscience, Inc. (VIVO) on Tuesday updated its earnings guidance for the full-year 2019, based on the pending acquisition of the business of GenePOC Inc.

For fiscal 2019, the company now expects the transaction to be dilutive to its previous full year adjusted earnings guidance range of $0.60 to $0.65 per share by about $0.10 to $0.12 per share, based on current purchase accounting estimates.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $0.66 per share for the year. Analysts' estimates typically exclude special items.

Further, the Board of Directors also suspended the company's quarterly cash dividend in connection with the announcement of its agreement to acquire the business of GenePOC Inc. and decision to allocate capital to related and other growth initiatives.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lawyers for the state of Oklahoma urged a judge on Monday to hold Johnson & Johnson (JNJ) responsible for the country's opioid epidemic. Oklahoma Attorney General Mike Hunter, in his closing arguments of the eight-week trial in Cleveland County, called the pharmaceutical company the "Kingpin" behind... Pizza chain Blaze Pizza has announced plans to offer a keto-diet-approved pizza crust, which will only have 6 grams of carbs. The pizza chain will swap flour for ingredients like flaxseeds, eggs, and cheese to offer the first-ever official keto-diet approved pizza. "As the first national chain... Even as Amazon.com Inc. kicked off its Prime Day annual shopping event on Monday, employees are expressing their dissatisfaction with the company. This year's Prime Day, Amazon's biggest celebration of deals, kick-started officially on Monday with more than one million offers for Prime Members in select countries around the world. The 48-hour extravaganza is the longest Prime Day ever.
Follow RTT